Welcome to our dedicated page for Elevation Oncolo SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elevation Oncology filings document the company’s transition from a Nasdaq-listed oncology issuer to a deregistered public-company record following its acquisition by Concentra Biosciences. The formal record includes 8-K disclosure of the completed tender offer for common stock and related contingent value rights, Nasdaq Form 25 removal from listing and Form 15 termination or suspension of Exchange Act reporting obligations.
The filings also cover material agreements tied to the company’s drug-development portfolio, including termination of the CSPC license for EO-3021, a Claudin 18.2 antibody-drug conjugate. These disclosures frame the company’s capital structure, corporate status, listing history, merger-related events and remaining public-reporting obligations.
Elevation Oncology, Inc. Schedule 13G/A discloses that Tang Capital entities and Kevin Tang beneficially own 3,115,000 shares of common stock, representing 4.997% of the class on a fully-diluted basis. The 3,115,000 shares are currently issuable upon exercise of warrants that are immediately exercisable and expire five years from issuance. The filing states the 62,338,729-share denominator used (59,223,729 outstanding as of May 9, 2025 plus 3,115,000 warrants). Voting and dispositive power over these shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang. The filing affirms these holdings are not for control purposes.
Several Frazier Life Sciences funds and named individuals filed a Schedule 13G/A reporting that they hold no beneficial ownership of Elevation Oncology common stock. Each Reporting Person discloses 0.00 shares and 0.0% of the class, with zero sole or shared voting power and zero sole or shared dispositive power. The statement includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer.
The filing identifies the reporting entities as multiple Frazier Life Sciences partnerships and affiliated entities and names the Members as James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes. A Joint Filing Agreement is incorporated by reference. Given the reported aggregate ownership of zero, this disclosure does not change the companys ownership or voting structure.
BML Investment Partners, L.P. has filed Amendment No. 1 to Schedule 13D regarding its prior position in Elevation Oncology, Inc. (ELEV). The filing states that, as of 23 July 2025, a Merger Agreement was consummated through a tender offer by an unaffiliated “Merger Sub” that purchased all outstanding shares of Elevation Oncology common stock. Following the closing, BML Investment Partners reports 0 shares beneficially owned, representing 0 % of the class.
• Voting and dispositive power: 0 shares sole or shared.
• Source of funds: “WC” (working capital) is listed, but no new capital was deployed as the position has been exited.
• No contracts, arrangements, or legal proceedings related to the securities are disclosed, and the reporting persons confirm no criminal or civil violations within the past five years.
The amendment principally serves to formally terminate BML’s reporting obligations by documenting its complete divestiture after the successful tender offer.